S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
AAPL   318.73 (+1.11%)
FB   222.14 (+0.17%)
MSFT   167.10 (+0.56%)
GOOGL   1,479.52 (+2.02%)
AMZN   1,864.72 (-0.70%)
CGC   24.89 (+2.43%)
NVDA   249.28 (+0.14%)
BABA   227.43 (+1.56%)
MU   57.66 (-0.03%)
GE   11.81 (-0.25%)
TSLA   510.50 (-0.58%)
AMD   50.93 (+2.33%)
T   38.38 (+0.92%)
ACB   2.13 (-0.93%)
F   9.16 (-0.11%)
NFLX   339.67 (+0.31%)
PRI   128.43 (+0.05%)
BAC   34.71 (-0.03%)
GILD   62.98 (-0.35%)
DIS   144.33 (-0.54%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
AAPL   318.73 (+1.11%)
FB   222.14 (+0.17%)
MSFT   167.10 (+0.56%)
GOOGL   1,479.52 (+2.02%)
AMZN   1,864.72 (-0.70%)
CGC   24.89 (+2.43%)
NVDA   249.28 (+0.14%)
BABA   227.43 (+1.56%)
MU   57.66 (-0.03%)
GE   11.81 (-0.25%)
TSLA   510.50 (-0.58%)
AMD   50.93 (+2.33%)
T   38.38 (+0.92%)
ACB   2.13 (-0.93%)
F   9.16 (-0.11%)
NFLX   339.67 (+0.31%)
PRI   128.43 (+0.05%)
BAC   34.71 (-0.03%)
GILD   62.98 (-0.35%)
DIS   144.33 (-0.54%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
AAPL   318.73 (+1.11%)
FB   222.14 (+0.17%)
MSFT   167.10 (+0.56%)
GOOGL   1,479.52 (+2.02%)
AMZN   1,864.72 (-0.70%)
CGC   24.89 (+2.43%)
NVDA   249.28 (+0.14%)
BABA   227.43 (+1.56%)
MU   57.66 (-0.03%)
GE   11.81 (-0.25%)
TSLA   510.50 (-0.58%)
AMD   50.93 (+2.33%)
T   38.38 (+0.92%)
ACB   2.13 (-0.93%)
F   9.16 (-0.11%)
NFLX   339.67 (+0.31%)
PRI   128.43 (+0.05%)
BAC   34.71 (-0.03%)
GILD   62.98 (-0.35%)
DIS   144.33 (-0.54%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
AAPL   318.73 (+1.11%)
FB   222.14 (+0.17%)
MSFT   167.10 (+0.56%)
GOOGL   1,479.52 (+2.02%)
AMZN   1,864.72 (-0.70%)
CGC   24.89 (+2.43%)
NVDA   249.28 (+0.14%)
BABA   227.43 (+1.56%)
MU   57.66 (-0.03%)
GE   11.81 (-0.25%)
TSLA   510.50 (-0.58%)
AMD   50.93 (+2.33%)
T   38.38 (+0.92%)
ACB   2.13 (-0.93%)
F   9.16 (-0.11%)
NFLX   339.67 (+0.31%)
PRI   128.43 (+0.05%)
BAC   34.71 (-0.03%)
GILD   62.98 (-0.35%)
DIS   144.33 (-0.54%)
Log in

NASDAQ:OTLK - Outlook Therapeutics Stock Price, Forecast & News

$1.04
+0.06 (+6.12 %)
(As of 01/17/2020 04:00 PM ET)
Today's Range
$1.00
Now: $1.04
$1.08
50-Day Range
$0.52
MA: $0.97
$1.59
52-Week Range
$0.52
Now: $1.04
$10.96
Volume822,887 shs
Average Volume1.88 million shs
Market Capitalization$29.36 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.9
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibody for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic bevacizumab product candidate that is in first clinical trial for the treatment of wet age related macular degeneration and other retina diseases. The company has collaboration and license agreements with MTTR, LLC; IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in December 2018. The company was founded in 2010 and is headquartered in Cranbury, New Jersey.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:OTLK
CUSIPN/A
CIKN/A
Phone609-619-3990

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$8.15 million
Book Value($0.57) per share

Profitability

Net Income$-34,520,000.00
Net Margins-423.83%

Miscellaneous

Employees56
Market Cap$29.36 million
Next Earnings Date2/13/2020 (Estimated)
OptionableNot Optionable

Receive OTLK News and Ratings via Email

Sign-up to receive the latest news and ratings for OTLK and its competitors with MarketBeat's FREE daily newsletter.


5G Flaw Exposed: $5 Stock Holds Key To $12 Trillion Opportunity (Ad)


A devastating technical glitch could crush the next generation of wireless technology before it even launches. With trillions of dollars and millions of jobs at stake, one company with the "5G fix" could put as much as $234,770 in your pocket this year. But Wall Street vultures are circling... you'll need to move quickly or risk missing this $5 bargain.

Outlook Therapeutics (NASDAQ:OTLK) Frequently Asked Questions

What is Outlook Therapeutics' stock symbol?

Outlook Therapeutics trades on the NASDAQ under the ticker symbol "OTLK."

When did Outlook Therapeutics' stock split? How did Outlook Therapeutics' stock split work?

Outlook Therapeutics's stock reverse split before market open on Monday, March 18th 2019. The 1-8 reverse split was announced on Friday, March 15th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Friday, March 15th 2019. An investor that had 100 shares of Outlook Therapeutics stock prior to the reverse split would have 13 shares after the split.

How were Outlook Therapeutics' earnings last quarter?

Outlook Therapeutics, Inc. (NASDAQ:OTLK) issued its quarterly earnings results on Thursday, December, 19th. The company reported ($0.12) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.31) by $0.19. The firm earned $5.85 million during the quarter, compared to the consensus estimate of $0.63 million. View Outlook Therapeutics' Earnings History.

When is Outlook Therapeutics' next earnings date?

Outlook Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February 13th 2020. View Earnings Estimates for Outlook Therapeutics.

What price target have analysts set for OTLK?

5 equities research analysts have issued twelve-month price objectives for Outlook Therapeutics' shares. Their forecasts range from $4.00 to $12.00. On average, they expect Outlook Therapeutics' stock price to reach $9.00 in the next year. This suggests a possible upside of 765.4% from the stock's current price. View Analyst Price Targets for Outlook Therapeutics.

What is the consensus analysts' recommendation for Outlook Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Outlook Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Outlook Therapeutics.

Has Outlook Therapeutics been receiving favorable news coverage?

News articles about OTLK stock have been trending positive this week, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Outlook Therapeutics earned a daily sentiment score of 3.0 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the next few days. View News Stories for Outlook Therapeutics.

Are investors shorting Outlook Therapeutics?

Outlook Therapeutics saw a increase in short interest during the month of December. As of December 31st, there was short interest totalling 2,000,000 shares, an increase of 13.6% from the December 15th total of 1,760,000 shares. Based on an average trading volume of 861,100 shares, the short-interest ratio is presently 2.3 days. Approximately 14.2% of the shares of the company are sold short. View Outlook Therapeutics' Current Options Chain.

Who are some of Outlook Therapeutics' key competitors?

What other stocks do shareholders of Outlook Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Outlook Therapeutics investors own include AzurRx BioPharma (AZRX), Onconova Therapeutics (ONTX), Biocept (BIOC), Sierra Oncology (SRRA), Big 5 Sporting Goods (BGFV), Lockheed Martin (LMT), FuelCell Energy (FCEL), Strongbridge Biopharma (SBBP), SCYNEXIS (SCYX) and VBI Vaccines (VBIV).

Who are Outlook Therapeutics' key executives?

Outlook Therapeutics' management team includes the folowing people:
  • Mr. Lawrence A. Kenyon, Pres, CEO, CFO, Company Sec., Treasurer & Director (Age 53)
  • Dr. Pankaj Mohan, Founder & Director (Age 54)
  • Dr. Kenneth M. Bahrt, Chief Medical Officer (Age 66)
  • Mr. Terry Dagnon, Chief Operating Officer (Age 57)
  • Rick Gregory, Director of Marketing & Communications

How do I buy shares of Outlook Therapeutics?

Shares of OTLK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Outlook Therapeutics' stock price today?

One share of OTLK stock can currently be purchased for approximately $1.04.

How big of a company is Outlook Therapeutics?

Outlook Therapeutics has a market capitalization of $29.36 million and generates $8.15 million in revenue each year. The company earns $-34,520,000.00 in net income (profit) each year or ($1.98) on an earnings per share basis. Outlook Therapeutics employs 56 workers across the globe.View Additional Information About Outlook Therapeutics.

What is Outlook Therapeutics' official website?

The official website for Outlook Therapeutics is http://www.outlooktherapeutics.com/.

How can I contact Outlook Therapeutics?

Outlook Therapeutics' mailing address is 7 CLARKE DRIVE, CRANBURY NJ, 08512. The company can be reached via phone at 609-619-3990 or via email at [email protected]


MarketBeat Community Rating for Outlook Therapeutics (NASDAQ OTLK)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  78 (Vote Outperform)
Underperform Votes:  80 (Vote Underperform)
Total Votes:  158
MarketBeat's community ratings are surveys of what our community members think about Outlook Therapeutics and other stocks. Vote "Outperform" if you believe OTLK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OTLK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/17/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel